Cargando…
Targeted therapy for cisplatin‐resistant lung cancer via aptamer‐guided nano‐zinc carriers containing USP14 siRNA
Cisplatin (DDP) is a common therapeutic option for non‐small cell lung carcinoma (NSCLC). However, some patients fail to respond to the DDP chemotherapy. Therefore, identifying novel biomarkers to improve the diagnosis and treatment of NSCLC is important. Ubiquitin‐specific protease (USP14) is invol...
Autores principales: | Zhao, Xinmin, Wu, Xianghua, Wang, Huijie, Lai, Songtao, Wang, Jialei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077057/ https://www.ncbi.nlm.nih.gov/pubmed/37035133 http://dx.doi.org/10.1002/mco2.237 |
Ejemplares similares
-
Correction to: Targeted therapy for cisplatin‐resistant lung cancer via aptamer‐guided nano‐zinc carriers containing USP14 siRNA
por: Zhao, Xinmin, et al.
Publicado: (2023) -
Aptamer mediated siRNA delivery
por: Chu, Ted C., et al.
Publicado: (2006) -
Thermal Stability of siRNA Modulates Aptamer- conjugated siRNA Inhibition
por: Berezhnoy, Alexey, et al.
Publicado: (2012) -
Fast degrading polyesters as siRNA nano-carriers for pulmonary gene therapy
por: Nguyen, Juliane, et al.
Publicado: (2008) -
Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study
por: Hu, Zhihuang, et al.
Publicado: (2022)